MACULAR DEGENERATION

This study tests a new medicine called tiespectus (also known as MK-8748 or EYE201) for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 960 people with untreated wet AMD will receive either tiespectus or the standard treatment aflibercept via eye…

This study tests a new medicine called tiespectus (EYE201) against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 960 adults with untreated wet AMD will receive eye injections and be followed for a year to see if…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier trials for geographic atrophy, a form of advanced age-related macular degeneration. The goal is to check long-term safety by monitoring eye health and side effects over time. Abou…

This early study tests a new dye called MB-102 for eye imaging (angiography) in 10 people with or without retinal diseases like diabetic retinopathy or macular degeneration. The goal is to see if MB-102 is safe and produces clear images compared to the standard dye, fluorescein s…

This study tests whether a gentle electrical brain stimulation (tDCS) can make reading training more effective for people with age-related or juvenile macular degeneration. About 30 adults will do six reading training sessions, half with real stimulation and half with fake (sham)…

This study looks at how people with severe vision loss from macular degeneration can train their brains to use their remaining side vision more effectively. Researchers will measure changes in visual skills after about 7 weeks of training. The goal is to learn more about brain pl…

This study tests whether 5 weeks of eye-tracking exercises with sound and visual cues can help people with central vision loss use their peripheral vision more effectively. About 12 participants with macular degeneration will do tasks that train eye movements while getting real-t…

This study follows 1,000 people with geographic atrophy (an advanced form of age-related macular degeneration) who are already being treated with the drug Izervay. Researchers will collect information from medical records and patient surveys over up to 5 years to see how the drug…

This study looks at how color vision loss progresses in people with inherited retinal diseases (IRDs) and how it relates to changes in the retina. Researchers will test a new color vision test designed for people with very low vision. The study involves 200 participants, includin…